Syndicated News

This blog is still in BETA

We are aware of any formatting errors. These stories are automatically pulled from RSS feeds. Due to the automated nature of the post, some images may appear small, and some links may not be clickable until our staff has had the opportunity to manicure the postings. Thank you for understanding.

March 13, 2015

Baxter's latest hemophilia drug comes through in Phase III - FierceBiotech

March 13, 2015/

http://ift.tt/1FYA6zZ Click to read full article...

Baxter's latest hemophilia drug comes through in Phase IIIFierceBiotechThe drug, BAX 817, is designed to replace the missing blood factors that stop blood from clotting normally and cause hemophilia. Many hemophilia patients come to develop inhibitors of such factor-replacement therapies, and Baxter's latest treatment is ...Baxter BioScience Announces Positive Phase III Results for BAX 817 ...MarketWatchall 6 news articles »

from Hemophilia - Google News http://ift.tt/1FYA6zZ via IFTTT

Committee of Ten Thousand

ADVOCATES FOR PERSONS WITH HIV/AIDS, HEMOPHILIA, HCV, AND SICKLE CELL

MONITORING THE BLOOD SUPPLY AND PROTECTING PATIENT RIGHTS SINCE 1989

The Committee of Ten Thousand is a grass-roots, peer-led, education, advocacy and support organization. The majority of our constituency is persons with hemophilia who contracted HIV/AIDS from tainted blood products. We work in solidarity with all communities affected by the HIV/AIDS pandemic. COTT advocates for disenfranchised chronic disease communities, especially those communities dependent on a safe national blood supply. We are dedicated to the belief that persons with HIV/AIDS and all chronic diseases can lead productive and healthy lives.

Syndicated News

Syndicated News Feed

Baxter's latest hemophilia drug comes through in Phase III - FierceBiotech

Committee of Ten Thousand

Quick Links - Sections